Veru is a biopharmaceutical company. Co.'s infectious disease clinical development program includes: COVID-19 patients at risk for acute respiratory distress syndrome; and Sabizabulin, a microtubule disruptor. Co.'s oncology clinical development program includes: breast cancer, which consist of Enobosarm, a selective androgen receptor and Sabizabulin, a microtubule disruptor; and prostate cancer, which include Sabizabulin, a microtubule disruptor, VERU-100, a GnRH antagonist depot and Zuclomiphene citrate, an oral nonsteroidal estrogen receptor agonist. Co.'s sexual health program include ENTADFI, for the treatment of benign prostatic hyperplasia. The VERU YTD return is shown above.
The YTD Return on the VERU YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether VERU YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VERU YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|